Co-Diagnostics FY2025 revenue drops 85% to $0.6M; net loss $46.9M; cash burn accelerates

Co-Diagnostics, Inc.

2026-Q1 EPS reported -$4.06 revenue$145,954

Revenue fell to $0.6M from $3.9M in 2024; net loss was $46.9M ($35.25/share) vs $37.6M.
Cash at $11.9M, down from $29.7M; adjusted EBITDA loss improved to $28.0M from $33.5M.
Received CDSCO license for PCR Pro instrument in India; expanding to South Asia with $13B addressable market.
Planning initial FDA 510(k) for flu A/B/RSV test, dropping COVID from initial submission to accelerate timeline.
Closed stock offerings raising $10.8M; engaged Maxim Group for potential SPAC for CoSara.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Co-Diagnostics, Inc. reported full year ended December 31, 2025 results: revenue $0.6 million, net income net loss of $46.9 million, EPS $35.25 per share.

Period: full year ended December 31, 2025
Revenue: $0.6 million
Net income: net loss of $46.9 million
EPS: $35.25 per share
Result: reported results

Exact text from the filing

the development of molecular diagnostic tests, today announced its financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results: ● Revenue of $0.6 million, compared to $3.9 million in 2024, primarily due to lower grant revenue ● Operating expenses of $50.6 million, compared to $43.0 million in 2024, driven by a non-cash impairment

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Co-Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-014129

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.